[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vasopressor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vasopressor":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,79,105,141,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100562590","phase-3-canadian-critical-care-comparative-effectiveness-platform-100562590",false,"NCT06605144","Canadian Critical Care Comparative Effectiveness Platform","Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en Soins Critiques (CEPEC)","CEPEC","VASOPRESSOR DOMAIN There is no minimum age limit in the Vasopressor Domain.\n\nInclusion criteria:\n\n1. Ongoing vasopressor infusion to treat hypotension, or would be used to treat clinician-defined hypotension as part of usual care;\n2. MAP \\\u003C75 mmHg at any point;\n3. Patient expected to be in the ICU for \\>24 hours.\n\nExclusion criteria:\n\n1. Treating team does not have equipoise for at least two contiguous MAP target ranges in the CEPEC Vasopressor Domain;\n2. Acute traumatic brain injury (within 7 days or ongoing active treatment for elevated intracranial pressure);\n3. Acute subarachnoid hemorrhage (within 21 days);\n4. Acute spinal cord injury (within 7 days of injury or ongoing vasopressor therapy for suspected spinal cord ischemia);\n5. Lung, heart, liver, kidney transplant recipient (within 7 days);\n6. Patient expected to become an organ donor (Donor Neurologic Death - DND or Donation After Circulatory Death - DCD);\n7. More than 24 hours since meeting inclusion criteria in the ICU;\n8. Previously randomized into the CEPEC Vasopressor Domain or a confounding trial.\n\nPLATELET DOMAIN\n\nInclusion criteria:\n\n1. Adult patients (age ≥18 years) admitted to the ICU;\n2. Latest platelet count in this hospital admission \\\u003C50×109\u002FL;\n3. Planned to undergo a specified low-moderate bleeding risk invasive procedure.\n\nExclusion criteria:\n\n1. Ongoing major hemorrhage requiring blood products and\u002For surgical\u002F radiological intervention;\n2. Intracranial hemorrhage within prior 72 hours;\n3. Contraindications to platelet transfusion (e.g. thrombotic microangiopathies, heparin-induced thrombocytopenia, recent history of immune thrombocytopaenia, congenital platelet function defects);\n4. Known advance decision of refusing blood\u002Fblood component transfusions;\n5. Acute promyelocytic leukemia (APML);\n6. Death perceived as imminent or admission for palliation;\n7. Previously randomized into the CEPEC Platelet Domain or the T4P Trial;\n8. Fulfilled all the inclusion criteria and none of the exclusion criteria ≥72 hours.\n\nNUTRITION DOMAIN\n\nInclusion criteria:\n\n1. Critically ill patients ≥18 years of age;\n2. Are invasively mechanically ventilated (including endotracheal tube or tracheostomy);\n3. Orogastric\u002Fnasogastric tube in place; or have an in dwelling percutaneous gastric tube (with confirmed placement);\n4. Treating team has started or has the intention of providing enteral nutrition.\n\nExclusion criteria:\n\n1. Patients who have had gastrointestinal (GI) surgery; in the last 3 months and deemed not ready to receive possible bolus nutrition;\n2. Bowel obstruction or ischemia; active;\n3. Has a post-pyloric small bowel feeding tube;\n4. Active GI bleeding;\n5. Patient who is chronically receiving enteral nutrition.","ALL","18 Years",{"count":20,"type":21},5500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en soins Critiques (CEPEC) is an international multi-centered randomized adaptive platform clinical trial. CEPEC will evaluate supportive care interventions that are used routinely in intensive care units throughout the world.",[27,28,29,30],"Intensive Care Unit ICU","Vasopressor","Platelet","Nutrition",[32,33,28,29,34],"ICU","Adaptive platform trial","Enteral nutrition","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2025-03-23",{"date":43,"type":21},"2030-06-30",{"name":45,"class":46},"Université de Sherbrooke","OTHER",9,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100642042","caffeine-and-prophylactic-noradrenaline-requirement-during-cesarean-delivery-100642042","NCT07655245","Caffeine and Prophylactic Noradrenaline Requirement During Cesarean Delivery","Effect of Preoperative Oral Caffeine on Prophylactic Noradrenaline Requirement During Cesarean Delivery: A Double-blind Placebo-controlled Trial","Inclusion Criteria:\n\n* Full-term singleton pregnant (\\>37 weeks)\n* ASA II\n* undergoing elective cesarean section.\n\nExclusion Criteria:\n\n* Patient refusal\n* SBP \\\u003C 100 mmHg\n* Allergy to local anesthetics or caffeine\n* Coagulopathy (INR\\>1.4 or platelets \\\u003C75.000)\n* Preeclampsia","FEMALE","20 Years","40 Years",{"count":59,"type":21},62,[61],"NA","Spinal anesthesia is the preferred regional technique in obstetric practice because it provides high maternal satisfaction and eliminates the need for airway manipulation. Despite these advantages, it is frequently complicated by spinal anesthesia-induced hypotension , defined as a reduction in systolic blood pressure of more than 20% from baseline or an absolute SBP below 100 mmHg. Spinal hypotension can have serious consequences, including maternal hypoperfusion that may lead to neurological or renal dysfunction, as well as fetal acidosis and bradycardia, which can compromise neonatal outcomes. The present study aims to evaluate the effect of preoperative caffeine administration on noradrenaline requirements during spinal anesthesia in obstetric patients. Specifically, the objectives are to compare noradrenaline requirements between the study groups and to assess the incidence of hypotension in both groups.",[64,28],"Spinal Hypotension",[66,28,67],"Spinal anesthesia induced hypotension","Caffeine","NOT_YET_RECRUITING","2026-06-12",{"date":71,"type":39},"2026-06-17",{"date":73,"type":21},"2026-06-16",{"date":75,"type":21},"2026-09-19",{"name":77,"class":46},"Cairo University",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":78},"100638552","phase-2-effect-of-vasopressin-versus-norepinephrine-on-post-operative-mean-pulmonary-arterial-pressure-following-pulmonary-endarterectomy-surgery-100638552","NCT07614438","Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery,","Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery, a Randomized Open Label Trial","VANOPE","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patient scheduled for pulmonary endarterectomy surgery;\n* In women of childbearing potential: negative serum pregnancy test and use of adequate contraception;\n* Affiliation to the French social care service;\n* Patient able to understand and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* Mesenteric ischemia and\u002For acute coronary syndrome within the month preceding the intervention;\n* Patients with documented mesenteric artery stenosis;\n* Impossibility to insert the pulmonary artery catheter (anatomical or technical issue);\n* Preoperative administration of norepinephrine and\u002For inotropic drugs (dobutamine, isoproterenol, epinephrine) or patients assisted by veno-venous or veno-arterial ECMO before surgery;\n* Known allergy to the active substance vasopressin or to any of its excipients;\n* Concomitant coronary bypass procedure or other combined surgery (i.e. valve replacement);\n* mPAP\\\u003C25 mmHg on preoperative right heart catheterization;\n* Patient with preoperative natremia below 130 mol\u002FL;\n* Patient participating to another interventional clinical trial;\n* For females only: documented pregnancy or lactation;\n* Patient under tutorship, curatorship or legal protection;\n* Patient deprived of liberty.",{"count":88,"type":21},90,[90],"PHASE2","Chronic thromboembolic pulmonary hypertension (CTEPH), one of the leading causes of pulmonary hypertension (PH), is caused by the chronic obstruction of the pulmonary arteries following episode of pulmonary embolism. It is the only cause of PH which is accessible to a potential curative surgical treatment: the pulmonary endarterectomy (PEA). Because of their underlying disease (pulmonary hypertension and potential right heart dysfunction), anesthesia should be performed cautiously. Perioperative hemodynamic management often requires the administration of a vasopressor to maintain the arterial pressure above a specific threshold of 65 mmHg.\n\nLow dose of vasopressin increases systemic arterial pressure with minimal effects on the pulmonary circulation. This profile suggests that vasopressin may be an ideal agent for vasopressor support in the high-risk population of patients with pulmonary hypertension.\n\nTo date, there is no data on the use of vasopressin in patient undergoing PEA surgery. The interesting properties of vasopressin - specifically, its ability to increase systemic arterial resistance while having a low impact on pulmonary resistance and offering potential renal protective effects - are highly advantageous in the specific subset of patient scheduled for PEA.\n\nThe investigators aim to conduct a randomized single center open label study to compare the effect of vasopressin compared to norepinephrine on mean pulmonary artery pressure after PEA surgery.\n\nThe primary objective of this study is to determine whether the use of vasopressin compared to norepinephrine decrease the mean pulmonary artery pressure after PEA surgery.\n\nParticipation to the study involves follow up at day 30 following surgery.",[93,94,95,28],"Anesthesia","Pulmonary Hypertension","Chronic Pulmonary Thromboembolism","2026-05-29",{"date":98,"type":39},"2026-06-02",{"date":100,"type":21},"2026-08-01",{"date":102,"type":21},"2028-09-01",{"name":104,"class":46},"Fondation Hôpital Saint-Joseph",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":124,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100577740","phase-4-the-choice-of-vasopressor-to-prevent-postoperative-acute-kidney-injury-after-major-non-cardiac-surgery-100577740","NCT06802224","The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery","Norepinephrine vs Phenylephrine as the First-line Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-cardiac Surgery","VEGA-2","Inclusion Criteria:\n\n* Age 18 years or older\n* Surgery under general anesthesia with a surgery duration of 2 hours or more\n* Received intravenous vasopressors during surgery\n\nExclusion Criteria:\n\n* Cardiac surgery\n* Extra-corporeal membrane oxygenation\n* Organ transplantation\n* Obstetric procedures\n* Procedures on the kidney\n* Outpatient procedures\n* Already receiving NE or PE or inotropes before induction of anesthesia (at the time of anesthesia start)\n* American Society of Anesthesiologists physical status classification 5 or 6\n* Patient for whom a local protocol recommends a specific first line vasopressor\n* Most recent documented estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73m\\^2 or preoperative renal replacement therapy within 60 days before surgery\n* Patients who do not have a preoperative creatinine value within 60 days before surgery\n* Alive patients who do not have a postoperative creatinine value",{"count":114,"type":21},18000,[116],"PHASE4","Low blood pressure, also known as hypotension, is very common during major surgery under general anesthesia. Prolonged or severe hypotension can lead to complications such as kidney injury after surgery that slow down patient recovery. Anesthesiologists commonly administer medications called vasopressors to treat low blood pressure during surgery. These medications help raise the blood pressure back up to a safe range. Two vasopressor medications are commonly used for this purpose: norepinephrine and phenylephrine. Each of these medications has slightly different effects on the heart and blood vessels (cardiovascular system). It remains unknown which of these standard medications is better for treating low blood pressure during surgery. The goal of this clinical trial is to determine which of these two medications is better at preventing injury to the kidneys after major noncardiac surgery as well as other complications such as heart problems. Major surgeries are defined as those lasting at least two hours under general anesthesia. This trial will randomize about ten centers in North America to use either norepinephrine or phenylephrine as the primary medication to treat low blood pressure in adults undergoing major noncardiac surgery. Each hospital will prioritize one of the drugs each month, and the assigned drug will rotate each month at each hospital. No further participant involvement will be required as de-identified data are collected as part of standard medical care.",[93,119,120,121,122,123,28],"Surgery With General Anesthesia","Noncardiac Surgery","Hypotension During Surgery","Acute Kidney Injury (AKI)","Myocardial Injury After Noncardiac Surgery (MINS)",[125,126,127,128,129,130],"Norepinephrine","Phenylephrine","Major adverse kidney events","Pragmatic","Cluster randomized","Crossover","2026-05-20",{"date":133,"type":39},"2026-05-26",{"date":135,"type":39},"2025-04-01",{"date":137,"type":21},"2028-07",{"name":139,"class":46},"University of California, San Francisco",10,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":162,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":78},"100591559","importance-of-arterial-measurement-sites-ipams-on-intraoperative-hemodynamic-management-100591559","NCT06982001","ImPortance of Arterial Measurement Sites (IPAMS) on Intraoperative Hemodynamic Management","Importance of Arterial Measurement Sites on Intraoperative Hemodynamic Management of Major Abdominal Surgeries and Artificial Intelligence-based Prediction of Arterial Gradient Using Peripheral Radial Pressure Waveform Analysis","IPAMS","Inclusion Criteria:\n\n* Patients between 18 and 90 years of age;\n* Major abdominal surgery via laparoscopy or laparotomy under general anesthesia - with or without concomitant use of regional or neuraxial anesthesia;\n* Expected anesthesia time of more than 120 minutes.\n\nExclusion Criteria:\n\n* Known peripheral severe vascular disease with subclavian artery stenosis,\n* Significant arterial gradient between arms with preoperative non-invasive bloop pressure measurements (\\>25 mm Hg of systolic blood pressure or 10 mm Hg of mean arterial pressure);\n* Inability or contraindications to insert arterial line on either arm (arteriovenous fistula, surgical sterility);\n* Known allergies, intolerance, other medical conditions that precludes the use of prescribed general anesthesia protocol for this trial;\n* Inability to communicate in French or English.","90 Years",{"count":151,"type":21},204,[61],"The goal of this clinical trial is to demonstrate the importance of arterial pressure measurement sites during major abdominal surgeries. This randomized controlled trial will compare arterial pressure measurements obtained from radial artery catheterization (the current standard method of monitoring) with those obtained from brachial artery catheterization (a more accurate reflection of central arterial pressure). At the end of the study, we are looking to answer the following questions:\n\n1. Does arterial pressure measurement sites influence the amount of vasopressors that is administered during major abdominal surgeries?\n2. What are the instances where there is a difference between peripheral (radial catheter) and central (brachial catheter) monitoring and what are the risk factors leading to the appearance of this radial-brachial pressure gradient?\n3. With the data collected, can artificial intelligence based analysis help predict the reliability of a radial monitoring and help guide clinicians on choosing a peripheral versus central arterial pressure monitoring site? All adult participants who are scheduled for elective major abdominal surgeries and meeting our inclusion criteria will be approached and included if they consent. Participants will be randomized 1:1 in the intervention group and the standard of care group. In the intervention group, the brachial arterial line will be used intraoperatively to guide vasopressor and fluid administration. A radial line will also be installed to measure the radial arterial pressure simultaneously, but will not be used to guide hemodynamic management. In the standard of care group, both lines will be installed just like in the intervention group, however, it is the radial arterial line that will guide fluid and vasopressor administration. In both groups, the anesthesia protocol will be standardized and the anesthesiologist will be blinded to the arterial pressure measurement site.",[155,156,157,158,93,28,159,160,161],"Perioperative Care","Hemodynamics","Monitoring Blood Pressure","Arterial Lines","Fluid Management","Artificial Intelligence in Operating Room","Artificial Intelligence (AI)",[163,164,165,166,167],"Comparison of arterial catheterization sites on hemodynamic monitoring","Incidence of radial-brachial pressure gradient","Risk factors of radial-brachial pressure gradient","Effect of arterial catheterization sites on hemodynamic management","Effect of peripheral vs central arterial pressure measurements in intraoperative hemodynamic management","2025-05-13",{"date":170,"type":39},"2025-05-21",{"date":172,"type":21},"2025-09",{"date":174,"type":21},"2028-12",{"name":176,"class":46},"Ciusss de L'Est de l'Île de Montréal",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":78},"100582217","observational-study-about-the-use-of-perfusion-index-to-use-vasopressor-in-sepsis-100582217","NCT06860438","Observational Study About the Use of Perfusion Index to Use Vasopressor in Sepsis","Can Perfusion Index Indicate the Need of Vasopressor in ICU Patients with Sepsis and Septic Shock, Prospective Observational Study","Inclusion Criteria:\n\n\\- All ICU patients with clinically suspected sepsis and septic shock ( signs include fever hypotension oliguria and confusion combined with culture results showing infection .Septic shock is a subset of sepsis involves persistent hypotension (mean arterial pressure ≥ 65 mm Hg, and a serum lactate level \\> 18 mg\u002FdL \\[2 mmol\u002FL)not responding to fluid resuscitation ) .\n\nExclusion Criteria:\n\n* Pregnant females\n* Patients on vasopressor or positive inotropic drugs\n* Patients with hypothermia (defined as central temperature \\\u003C35°C).\n* Patient with impairment of upper extremity circulation,(such as those who underwent radial artery harvesting for coronary artery bypass grafting or had suspected occlusion of the radial artery prior to surgery,)\n* Patients had undergone an operation that involved the large arteries of the aortic arch.\n* Patients with atherosclerosis .",{"count":185,"type":21},40,"OBSERVATIONAL","In this thesis we will use the current state of knowledge that PI can provide a reliable information about the state of peripheral microcirculation during the state of sepsis and septic shock in ICU patients and that can interfere with the timing of starting vasopressor treatment in sepsis and septic shock",[189,190,28],"Sepsis","Perfusion Index","2025-03-03",{"date":193,"type":39},"2025-03-06",{"date":195,"type":39},"2024-08-01",{"date":197,"type":21},"2025-03",{"name":199,"class":46},"Ain Shams University"]